Josef Brueggen

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Carlos Garcı́a-Echeverrı́a, Mark Pearson, Andreas Marti et al. · Cancer Cell · 2004 · 538 citations · Full text

Medicine, Medicinal Chemistry, Oncology +9

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

AEE788

Peter Traxler, Peter R. Allegrini, Ralf Brandt et al. · Cancer Research · 2004 · 318 citations

Medicine, Oncology, Pharmacology +17

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski et al. · Breast Cancer Research · 2008 · 225 citations · Full text

Medicine, Oncology, Pharmacology +13